Leitlinie Nr. 24b der DOG und BVA

Deutsche Ophthalmologische Gesellschaft; Berufsverband der Augenärzte Deutschlands e.V.

doi:10.1055/s-0043-124499

Klinische Monatsblätter für Augenheilkunde, Inhaltsverzeichnis

Klin Monbl Augenheilkd 2018; 235(01): 94-107
DOI: 10.1055/s-0043-124499

Leitlinien

Georg Thieme Verlag KG Stuttgart · New York

Leitlinie Nr. 24b der DOG und BVA^[*]

Nichtinfektiöse Uveitis posteriorDOG and BVA Guideline No. 24bNoninfectious uveitis posterior Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augenärzte Deutschlands e.V.

Abstract

Volltext

Referenzen

Literatur
1 Absasolo L, Rosales Z, Diaz-Valle D. et al. Immunosuppressive drugs discontinuation in noninfectious uveitis from real-life clinical practice: a survival analysis. Am J Ophthalmol 2016;
2 Adan A, Mesquida M, Llorenc V. et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2627-2632 (III)
3 Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978; 96: 247-251
4 Androudi S, Tsironi E, Kalogeropoulos C. et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117: 1612-1616 (III)
5 Arida A, Fragiadaki K, Giavri E. et al. Anti-TNF agents for Behçetʼs disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70 10.1016/j.semarthrit.2010.09.002
6 Artornsombudh P, Gevorgyan O, Payal A. et al. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology 2013; 120: 588-592 (III)
7 Baltatzis S, Tufail F, Yu EN. et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003; 110: 1061-1065 (III)
8 Baughman RP, Lower EE, Bradley DA. et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-1047 (Ib)
9 Becker MD, Heiligenhaus A, Hudde T. et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005; 89: 1254-1257 (III)
10 BenEzra D, Cohen E, Chajek T. et al. Evaluation of conventional therapy versus cyclosporine A in Behçetʼs syndrome. Transplant Proc 1988; 20: 136-143 (Ib)
11 Berufsverband der Augenärzte Deutschlands e.V. (BVA), Deutsche Ophthalmologische Gesellschaft. Leitlinien von BVA und DOG. 2013 Im Internet: http://www.augeninfo.de/leit/leitvo.htm
12 http://cms.augeninfo.de/fileadmin/stellungnahmen/Stellungnahme_zur_Therapie_der_chorioidalen_Neovaskularisation Stand: 26.9.2017
13 http://cms.augeninfo.de/fileadmin/stellungnahmen/Stellungnahme_Ocriplasmin_01.pdf Stand: 26.9.2017
14 Callanan DG, Jaffe GJ, Martin DF. et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201 (Ib)
15 Calvo-Río V, Blanco R, Beltrán E. et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçetʼs disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014; 53: 2223-2231 (Ib)
16 Cruz BA, Reis DD, Araujo CA. Minas Gerais Vasculitis Study Group. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 2007; 27: 1181-1183
17 Davatchi F, Shams H, Rezaipoor M. et al. Rituximab in tractable ocular lesions of Behcetʼs disease: randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13: 246-252
18 De Smet MD, Taylor SR, Bodaghi B. et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011; 30: 452-470 10.1016/j.preteyeres.2011.06.005 (IV)
19 de Vries J, Baarsma GS, Zaal MJ. et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990; 74: 344-349 (Ib)
20 Deuter CM, Doycheva D, Stuebiger N. et al. Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm 2009; 17: 415-419 (III)
21 Dick AD, Tundia N, Sorg R. et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 2016; 123: 655-662 (IIb)
22 http://www.dog.org/wp-content/uploads/2013/03/zur-intravitrealen-Therapie-des-Makulaoedems-bei-Uveitis-Stand-02.07.2014.pdf Stand: 26.9.2017
23 Doycheva D, Jägle H, Zierhut M. et al. Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up. Br J Ophthalmol 2015; 99: 87-91 (III)
24 Dunn JP. Review of immunosuppressive drug therapy in uveitis. Curr Opin Ophthalmol 2004; 15: 293-298 (III)
25 http://www.dv-osteologie.org/uploads/Leitlinie/2014/DVO-Leitlinie/Osteoporose/2014/Kitteltaschenversion/15.12.2014.pdf Stand: 26.9.2017
26 Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012; 2: 21-28 (IV)
27 Engelhard SB, Patel V, Reddy AK. Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA. Clin Ophthalmol 2015; 9: 1549-1555 (III)
28 Farvardin M, Afarid M, Mehryar M. et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30: 1530-1535 (III)
29 Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol 2016; 173: 680-692 (III)
30 French Behçet Network. Vallet H, Riviere S, Sanna A. et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçetʼs disease: multicenter study of 124 patients. J Autoimmun 2015; 62: 67-74 (Ib)
31 Galor A, Jabs DA, Leder HA. et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115: 1826-1832 (III)
32 Gangaputra S, Newcomb CW, Liesegang TL. et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009; 116: 2188-2198.e1 (III)
33 Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-1955 (Ia)
34 Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 2004; 12: 169-192 (IV)
35 Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye 1998; 12: 783-788 (III)
36 Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111: 491-500 (IIb)
37 Hatemi G, Silman A, Bang D. et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68: 1528-1534 (II)
38 Hazirolan D, Pleyer U. Think global-act local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res 2013; 49: 59-65 (IV)
39 Heiligenhaus A, Thurau S, Hennig M. et al. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1531-1551 (IV)
40 Heiligenhaus A, Breitbach M, Spital G. et al. Posteriore Uveitis Teil 1: Diagnose und Grundkonzepte der Therapie. Klin Monatsbl Augenheilkd 2014; 231: 457-469 (IV)
41 Heiligenhaus A, Breitbach M, Spital G. et al. Posteriore Uveitis. Teil 2: Die unterschiedlichen Krankheitsbilder. Klin Monatsbl Augenheilkd 2014; 231: 555-579 (IV)
42 Hogan AC, McAvoy CE, Dick AD. et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007; 114: 1000-1006 (III)
43 Islam SM, Tabbara KF. Causes of uveitis at the eye center in Saudi Arabia: a retrospective review. Ophthalmic Epidemiol 2002; 9: 239-249
44 Jabs DA, Rosenbaum JT, Foster CS. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492-513 (IIb)
45 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516 (IIb)
46 Jaffe GF, Dick AD, Brezin AP. et al. Adalimumab in patients with active non-infectious uveitis: VISUAL-1 Trial. N Engl J Med 2016; 375: 932 10.1056/NEJMoa1509852 (Ib)
47 Jakob E, Reuland MS, Mackensen F. et al. Uveitis subtypes in a German interdisciplinary uveitis center – analysis of 1916 patients. J Rheumatol 2009; 36: 127-136 (III)
48 Kacmaz RO, Kempen JH, Newcomb C. et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010; 117: 576-584 (Ib)
49 Kaplan-Messas A, Barkana Y, Avni I. et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003; 11: 131-139 (III)
50 Kempen JH, Gangaputra S, Daniel E. et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008; 146: 802-812 (Ib)
51 Kempen JH, Van Natta ML, Altaweel MM. et al. Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment (MUST) trial. Am J Ophthalmol 2015; 160: 1133-1141 (Ib)
52 Kreider ME, Hansen-Flaschen J, Ahmad NN. et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007; 83: 1140-1144 10.1016/j.athoracsur.2006.10.002
53 Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003; 31: 487-491 (III)
54 Lerman A, Lewen MD, Kempen JH. et al. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160: 193-200 (IIb)
55 Levy-Clarke G, Jabs DA, Read RW. et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785-796 (Ib)
56 Lowder C, Belfort jr. R, Lightman S. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553 (Ib)
57 Markomichelakis NN, Theodossiadis PG, Pantenelia E. et al. Infliximab for chronic macular edema associated with uveitis. Am J Ophthalmol 2004; 138: 648-650 (IV)
58 Markomichelakis NN, Demicha E, Masselos S. et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 2012; 154: 534-541 (IV)
59 Masuda K, Nakajima A, Urayama A. et al. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporin in Behçetʼs disease. Lancet 1989; 1: 1093-1096 (Ib)
60 Mochizuki M, Masuda K, Sakane T. et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115: 763-769 (IIa)
61 Murphy CC, Greiner K, Plskova J. et al. Cyclosporine vs. tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005; 123: 634-641 (Ib)
62 Nguyen QD, Merrill PT, Jaffe GJ. et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016;
63 Nussenblatt RB, Palestine AG, Chan CC. et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467-471 (Ib)
64 Nussenblatt RB, Palestine AG, Chan CC. et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991; 112: 138-146 (Ib)
65 Ozyazgan Y, Yurdakul S, Yazici H. et al. Low dose cyclosporin a versus pulsed cyclophosphamide in Behçetʼs syndrome: a single masked trial. Br J Ophthalmol 1992; 76: 241-243 (IIa)
66 Patel AK, Newcomb CW, Liesegang TL. et al. Risk of retinal neovascularization in cases of uveitis. Ophthalmology 2016; 123: 646-654 (IIb)
67 Pacheco PA, Taylor SR, Cuchacovich MT. et al. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 2008; 16: 161-165 (III)
68 Pleyer U, Stübiger N. New pharmacotherapy options for noninfectious posterior uveitis. Expert Opin Biol Ther 2014; 14: 1783-1799 (IV)
69 Pleyer U, Klamann M, Laurent TJ. et al. Fast and successful management of Intraocular inflammation with a single Intravitreal dexamethasone implant. Ophthalmologica 2014;
70 Pleyer U, Pohlmann D, Stübiger N. Therapie der posterioren, nichtinfektiösen Uveitis – aktueller Stand und künftige Entwicklungen. Ophthalmologe 2016; 113: 380-390 (IV)
71 Pleyer U, Algharably EA, Feist E. et al. Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opin Pharmacother 2017; 18: 1311-1323 10.1080/14656566.2017.1361408
72 Rathinam SR, Babu M, Thundikandy R. et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology 2014; 121: 1863-1870 (Ib)
73 http://www.rheumanet.ch/download/Content_attachments/FileBaseDoc/Steroid/2DOsteoporose/2D12/2D2013-D.pdf Stand: 26.9.2017
74 Roesel M, Gutfleisch M, Heinz C. et al. Intravitreal and orbital floor triamcinolone acetonide injections in non-infectious uveitis. A comparative study. Ophthalmic Res 2009; 42: 81-86 (III)
75 Roy M. Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 2007; 42: 634 (III)
76 Samson CM, Waheed N, Baltatzis S. et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-1139 (III)
77 Santos-Gomez M, Calvo-Rio V, Blanco R. et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcetʼs disease: results of a multicentre open-label study. Clin Exp Rheumatol 2016; 34 (Suppl. 102) S34-S40 (IV)
78 Schaap-Fogler M, Amer R, Friling R. et al. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 2014; 252: 633-640 (III)
79 Schilling H, Heiligenhaus A, Laube T. et al. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005; 25: 182-188 (III)
80 Siepmann K, Huber M, Stubiger N. et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788-794 (III)
81 Suhler EB, Smith JR, Giles TR. et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial letter. Arch Ophthalmol 2009; 127: 819-822 (Ib)
82 Suhler EB, Lowder CY, Goldstein DA. et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 2013; 97: 481-486 (Ib)
83 Takeuchi M, Kezuka T, Sugita S. et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçetʼs disease: a multicenter study. Ophthalmology 2014; 121: 1877-1884 (IIb)
84 Taylor SR, Banker A, Schlaen A. et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 2013; 33: 2149-2154 (III)
85 Teoh SC, Hogan AC, Dick AD. et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008; 146: 752-760.e3 10.1016/j.ajo.2008.03.004 (III)
86 The Multicenter Uveitis Steroid Treatment (MUST), Trial Follow-up Study Research Group. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis. Fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trail and follow-up study. Ophthalmology 2015; 122: 1967-1975 (Ib)
87 The Multicenter Uveitis Steroid Treatment (MUST), Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 2015; 122: 1976-1986 (Ib)
88 Thomas SS, Borazan N, Barroso N. et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015; 29: 241-258 (Ia)
89 Thorne JE, Jabs DA, Qazi FA. et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112: 1472-1477 (III)
90 Thorne JE, Skup M, Tundia N. et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol 2016; 94: 331-339
91 Udeotuk JD, Dai Y, Ying GS. et al. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology 2012; 119: 1569-1574 (IIb)
92 Yates WB, Yajdic CM, Na R. et al. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology 2015; 122: 265-273 (IIb)
93 Yazici H, Pazarli H, Barnes CG. et al. A controlled trial of azathioprine in Behçetʼs syndrome. N Engl J Med 1990; 322: 281-285 (Ib)

Leitlinie Nr. 24b der DOG und BVA[*]

Leitlinie Nr. 24b der DOG und BVA^[*]